Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2018 / N 3

Что нужно знать практическому врачу при назначении статинов?
Ю.А. Карпов

Список литературы

1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner @Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2016 Oct;37(39):2999-3058.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov;344(8934):1383-9.
3. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 Nov;376(9753):1670-81.
4. Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. European Heart Journal 2009 May;30(9):1046-56.
5. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015 Apr;385(9976):1397-405.
6. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007 Mar;297(12):1344-53.
7. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr;295(13):1556-65.
8. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012 Aug;380(9841):581-90.
9. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. The New England Journal of Medicine 2015 Jun;372(25):2387-97.
10. Sabatine MS, Giugliano RP, Pedersen TR. Evolocumab in patients with cardiovascular disease. The New England Journal of Medicine 2017 Aug;377(8):787-8.
11. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. Москва, 2017.
12. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics 2010 Apr;35(2):139-51.
13. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. International Journal of Clinical Practice 2005 Feb;59(2):239-52.
14. Lewis S, Olufade T, Anzalone D, Johnston S. Real-world changes in LDL-C among high-risk patients switching from atorvastanin to rosuvastatin. Journal of Clinical Lipidology 2016 Мay-June;10(3):691-2.
15. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. The American Journal of Geriatric Pharmacotherapy 2012 Aug;10(4):264-71.
16. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004 May;126(5):1287-92.
17. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology 2015 Sep;63(3):705-12.
18. Kjekshus J, Apetrei E, Barrios, B@öhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, J@ánosi A, Kamensk@ý G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. The New England Journal of Medicine 2007 Nov;357(22):2248-61.
19. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 Oct;372(9645):1231-9.
20. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. The American Journal of Cardiology 2006 Apr;97(8A):32C-43C.
21. Finegold JA, Francis DP. What proportion of symptomatic side-effects in patients taking statins are genuinely caused by the drug? A response to letters. European Journal of Preventive Cardiology 2015 Oct;22(10):1328-30.
22. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation 2013 Jan;127(1):96-103.
23. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P; ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017 Jun;389(10088):2473-81.
24. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokg@özo@ğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, M@ärz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal 2015 May;36(17):1012-22.
25. Law M, Rudnicka AR. Statin safety: a systematic review. The American Journal of Cardiology 2006 Apr;97(8A):52C-60C.
26. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Reviews of Pharmacology and Toxicology 1999;39:1-17.
27. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atherosclerosis Supplements 2002 May;3(1):35-40.
28. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS,Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. Journal of the American College of Cardiology 2014 Jun;63(23):2541-8.
29. Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. The Annals of Pharmacotherapy 2013 Mar;47(3):398-404.
30. Preiss D, Seshasai S, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011 Jun;305(24):2556-64.
31. Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. Journal of the American College of Cardiology 2013 Jan;61(2):148-52.
32. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. American Heart Journal 2004 Apr;147(4):705-13.
33. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010 Feb;375(9716):735-42.
34. Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. The Cochrane Database of Systematic Reviews 2014 Jan;(1):CD005019.
35. Vidt DG. Statins and proteinuria. Current Atherosclerosis Reports 2005 Sep;7(5):351-7.
36. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opinion on Drug Safety 2004 Nov;3(6):547-57.
37. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. Journal of the American College of Cardiology 2008 Jun;51(25):2375-84.
38. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Annals of Internal Medicine 2014 Feb;160(3):182.
39. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007;107(4):433-43.
40. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guideline for diabetes and chronic kidney disease (CKD) 2012 update. American Journal of Kidney Diseases 2012;60(5):850-86.
41. Томилова Д.И., Карпов Ю.А., Лопухова В.В. Долгосрочная приверженность терапии статинами после планового коронарного стентирования при стабильной стенокардии. Кардиология 2018;58(5):65-71.
42. Шальнова С.А., Деев А.Д., Метельская В.А., Евстифеева С.Е., Ротарь О.П., Жернакова Ю.В., Бойцов С.А., Баланова Ю.А., Гомыранова Н.В., Имаева А.Э., Капустина А.В., Концевая А.В., Литинская О.А., Мамедов М.Н., Муромцева Г.А., Оганов Р.Г., Суворова Е.И., Худяков М.Б., Баранова Е.И., Конради А.О., Шляхто Е.В., Ильин В.А, Касимов Р.А., Шабунова А.А, Калашников К.Н., Калачикова О.Н, Кондакова О.А, Попов А.В, Устинова Н.А., Азарин О.Г., Бабенко Н.И., Бондарцов Л.В., Минаков Э.В., Хвостикова А.Е., Фурменко Г.И., Недогода С.В., Ледяева А.А., Чумачек Е.В., Кулакова Н.В., Мокшина М.В., Невзорова В.А., Родионова Л.В., Шестакова Н.В., Белова О.А., Назарова О.А., Романчук С.В., Шутемова Е.А., Кавешников В.С., Карпов Р.С., Серебрякова В.Н., Трубачева И.А., Аристов А.И., Гринштейн Ю.И., Данилова Л.К., Евсюков А.А., Каскаева Д.С., Косинова А.А., Петрова М.М., Руф Р.Р., Топольская Н.В., Шабалин В.В., Шматова Е.Н., Барбараш О.Л., Артамонова Г.В., Скрипченко А.Е., Индукаева Е.В., Мулерова Т.А., Максимов С.А., Черкасс Н.В., Табакаев М.В., Данильченко Я.В., Басырова И.Р., Исаева Е.Н., Кондратенко В.Ю., Либис Р.А., Лопина Е.А., Сафонова Д.В., Гутнова С.К., Гатагонова Т.М., Толпаров Г.В., Гудкова С.А., Дупляков Д.В., Черепанова Н.А., Ефанов А.Ю., Медведева И.В., Сторожок М.А., Шава В.П., Шалаев С.В. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2016;15(4):29-37.
43. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. The American Journal of Medicine 2012 Sep;125(9):882-7.
44. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. The Cochrane Database of Systematic Reviews 2010 Mar;(3):CD004371.

References
1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2016 Oct;37(39):2999-3058.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov;344(8934):1383-9.
3. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 Nov;376(9753):1670-81.
4. Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. European Heart Journal 2009 May;30(9):1046-56.
5. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015 Apr;385(9976):1397-405.
6. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007 Mar;297(12):1344-53.
7. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr;295(13):1556-65.
8. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012 Aug;380(9841):581-90.
9. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. The New England Journal of Medicine 2015 Jun;372(25):2387-97.
10. Sabatine MS, Giugliano RP, Pedersen TR. Evolocumab in patients with cardiovascular disease. The New England Journal of Medicine 2017 Aug;377(8):787-8.
11. Diagnosis and treatment of lipid metabolism disorders to prevent and treat atherosclerosis. Russian guidelines. 6th revision. Moscow, 2017. (In Russian).
12. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics 2010 Apr;35(2):139-51.
13. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. International Journal of Clinical Practice 2005 Feb;59(2):239-52.
14. Lewis S, Olufade T, Anzalone D, Johnston S. Real-world changes in LDL-C among high-risk patients switching from atorvastanin to rosuvastatin. Journal of Clinical Lipidology 2016 Мay-June;10(3):691-2.
15. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. The American Journal of Geriatric Pharmacotherapy 2012 Aug;10(4):264-71.
16. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004 May;126(5):1287-92.
17. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology 2015 Sep;63(3):705-12.
18. Kjekshus J, Apetrei E, Barrios, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. The New England Journal of Medicine 2007 Nov;357(22):2248-61.
19. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 Oct;372(9645):1231-9.
20. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. The American Journal of Cardiology 2006 Apr;97(8A):32C-43C.
21. Finegold JA, Francis DP. What proportion of symptomatic side-effects in patients taking statins are genuinely caused by the drug? A response to letters. European Journal of Preventive Cardiology 2015 Oct;22(10):1328-30.
22. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation 2013 Jan;127(1):96-103.
23. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P; ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017 Jun;389(10088):2473-81.
24. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal 2015 May;36(17):1012-22.
25. Law M, Rudnicka AR. Statin safety: a systematic review. The American Journal of Cardiology 2006 Apr;97(8A):52C-60C.
26. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Reviews of Pharmacology and Toxicology 1999;39:1-17.
27. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atherosclerosis Supplements 2002 May;3(1):35-40.
28. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS,Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. Journal of the American College of Cardiology 2014 Jun;63(23):2541-8.
29. Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. The Annals of Pharmacotherapy 2013 Mar;47(3):398-404.
30. Preiss D, Seshasai S, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011 Jun;305(24):2556-64.
31. Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. Journal of the American College of Cardiology 2013 Jan;61(2):148-52.
32. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. American Heart Journal 2004 Apr;147(4):705-13.
33. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010 Feb;375(9716):735-42.
34. Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. The Cochrane Database of Systematic Reviews 2014 Jan;(1):CD005019.
35. Vidt DG. Statins and proteinuria. Current Atherosclerosis Reports 2005 Sep;7(5):351-7.
36. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opinion on Drug Safety 2004 Nov;3(6):547-57.
37. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. Journal of the American College of Cardiology 2008 Jun;51(25):2375-84.
38. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Annals of Internal Medicine 2014 Feb;160(3):182.
39. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007;107(4):433-43.
40. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guideline for diabetes and chronic kidney disease (CKD) 2012 update. American Journal of Kidney Diseases 2012;60(5):850-86.
41. Tomilova DI, Karpov YuA, Lopukhova VV. Long-term statin adherence in patients with stable angina after coronary stenting. Kardiologiia 2018;58(5):65-71 (In Russian).
42. Shalnova SA, Deyev AD, Metelskaya VA, Evstifeeva SE, Rotar OP, Zhernakova YuV, Boytsov SA, Balanova YuA, Gomyranova NV, Imayeva EA, Kapustina AV, Kontsevaya AV, Litynskaya OA, Mamedov MN, Muromtseva GA, Oganov RG, Suvorova EI, Khudyakov MB, Baranova EI, Konradi AO, Shlyakhto EV, Ilyin VA, Kasimov RA, Shabunova AA, Kalashnikov KN, Kalachikova ON, Kondakova OA, Popov AV, Ustinova NA, Azarin OG, Babenko NI, Bondartsov LV, Minakov EV, Khvostikova AE, Furmenko GI, Nedogoda SV, Ledyaeva AA, Chumachek EV, Kulakova NV, Mokshina MV, Nevzorova VA, Rodionova LV, Shestakova NV, Belova OA, Nazarova OA, Romanchuk S., Shutemova EA, Kaveshnikov VS, Karpov RS, Serebryakova VN, Trubacheva IA, Aristov AI, Greenstein YuI, Danilov LK, Evsyukov AA, Kaskaeva DS, Kosinova AA, Petrova MM, Ruph RR, Topolskaya NV, Shabalin VV, Shmatova EN, Barbarash OL, Artamonova GV, Skripchenko AE, Indukaeva EV, Mulerova TA, Maksimov SA, Cherkass NV, Tabakaev MV, Danilchenko YaV, Basyrova IR, Isaeva EN, Kondratenko VYu, Libis RA, Lopina EA, Safonova DV, Gutnova SK, Gatagonova TM, Tolparov GV, Gudkova SA, Duplyakov DV, Cherepanova NA, Efanov AYu, Medvedeva IV, Storozhok MA, Shava VP, Shalaev SV. Awareness and features of statin therapy in persons with different cardiovascular risk: ESSE-RF study. Cardiovascular Therapy and Prevention 2016;15(4):29-37 (In Russian).
43. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. The American Journal of Medicine 2012 Sep;125(9):882-7.
44. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. The Cochrane Database of Systematic Reviews 2010 Mar;(3):CD004371.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]